Canadian Mother-Child Cohort

The Canadian Mother-Child Cohort is a Canadian initiative bringing together real world data from various provinces to address a critical public health issue facing Canada and the rest of the world: the impact of prescription drug use during pregnancy on long-term health outcomes in both mother and child. The ultimate goal is to identify serious events associated with gestational medication use in a timely manner, which allows us to take preventive measures in order to avert or minimize them. The secondary objectives are to: * Develop and put in place large provincial mother-child longitudinal, population-based cohorts in Canada. * Develop standardized and harmonized tools (Common Data Models (CDM)/Definitions/Codes/Algorithms) to adequately and similarly identify pregnancy/child cohorts with longitudinal follow-ups. * Assess use, safety and effectiveness of drug use during pregnancy and in childhood. * Provide a surveillance system to evaluate and identify safety signals that can be used to rapidly answer queries from policy makers. * Find cost-effective health strategies and policies improving the health of mothers, children, and the overall Canadian population. * Develop a Canadian consortium of researchers, highly qualified personnel, and knowledge users that can continue to take an active leadership role in building an international collaborative network.

Overview

Acronym
CaMCCo
Website
CaMCCo
Investigators
Dr. Anick Bérard
Université de Montréal/CHU Ste-Justine
Dr. Tim Oberlander
University of British Columbia
Dr Sherif Eltonsy
University of Manitoba
Dr. Mark Walker
Ottawa Hospital Research Institute / University of Ottawa
Dr. Steven Hawken
University of Ottawa
Dr. Brandance Winquist
Saskatchewan Health Authority
Dr. Padma Kaul
University of Alberta
Dr. Évelyne Vinet
McGill University
Dr Bruce Carleton
University of British Columbia
Contacts
Dr. Anick Bérard
Université de Montréal/CHU Ste-Justine

General Design

Study design
Cohort
Start - End Year
1995 - 2022
General Information on Follow Up (profile, frequency)
* The follow-up is continuous through billing, hospital and socio-demographic databases in each province. * Women are followed from 12 months before the beginning of pregnancy, defined as the first day of the last menstrual period, until the end of pregnancy. * The children are followed from birth up to the end of the study.
Recruitment Target
  • Families
Number of Participants
No Limit
Supplementary information about number of participants
In 2022, the study included approximately 4 million Canadian pregnancies and 3.15 million children.

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Everyone requesting data access and doing statistical analyses are signing a confidentiality agreement form. All requests need to include at least one CaMCCO investigator to ensure harmonization of reporting. Access requests to CaMCCO for research purposes should be sent to A Bérard, and approved by the Steering Committee and provincial ethics committees.

Marker Papers

Bérard A, Sheehy O. The Quebec Pregnancy Cohort–prevalence of medication use during gestation and pregnancy outcomes. PloS one. 2014; 9(4):e9387

PUBMED 24705674

Timeline

Populations

CaMCCo - Mothers
The population is composed of pregnant women from the general population between 15 and 45 years of age from one of the participating provinces.

Selection Criteria

Sex
Women only
Minimum age
15
Maximum age
45
Pregnant Women
  • First trimester
  • Second trimester
  • Third trimester
Countries
  • Canada
Canadian Provinces
  • Alberta
  • British Columbia
  • Manitoba
  • Ontario
  • Quebec
  • Saskatchewan

Sources of Recruitment

General Population
  • Selected sample
Supplementary Information
Pregnant women were recruited from the governmental databases.

Sample Size

Number of Participants
No Limit

Data Collection Events

# Name Data sources Data sources - Biosamples Start End
0 CaMCCo - Mothers - Data capture
  • Questionnaires
  • Administrative databases
1995 2022
CaMCCo - Children
The population is composed of the newborns of mothers recruited for the CAMCCO study.

Selection Criteria

Newborns
Countries
  • Canada
Canadian Provinces
  • Alberta
  • British Columbia
  • Manitoba
  • Ontario
  • Quebec
  • Saskatchewan
Other Criteria
Singleton, and multiples liveborn babies of the women also included in the study.
Supplementary Information about selection criteria
The status of the newborn is obtained via the births and deaths database or by linking the mother-child hospital patient charts.

Sources of Recruitment

General Population
  • Selected sample
Supplementary Information
Newborns of participating mother were recruited from the governmental database.

Sample Size

Number of Participants
No Limit

Data Collection Events

# Name Data sources Data sources - Biosamples Start End
0 CaMCCo - Children - Data capture
  • Administrative databases
1995 2022

Participating Studies

Acronym Name Study design Countries

Harmonization Initiatives Included

Acronym Name

Datasets

Name Data Collection Events Variables

Areas of Information Collected

Socio-demographic and economic characteristics
Death
Lifestyle and behaviours
Physical measures and assessments
Birth, pregnancy and reproductive health history
Laboratory measures
Perception of health, quality of life, development and functional limitations
Cognition, personality and psychological measures and assessments
Diseases
Life events, life plans, beliefs and values
Symptoms and signs
Preschool, school and work life
Medication and supplements
Social environment and relationships
Non-pharmacological interventions
Physical environment
Health and community care services utilization
Administrative information

Variables Content Summary

Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected

Networks

Acronym Name Harmonization Initiatives Individual Studies
Last Update: 2024-02-27T12:22:18.668